Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile

Fertility and Sterility

Volumn 92, Issue 3, 2009, Pages 1025-1038

  Lobo, Rogerio A ^a   Pinkerton, JoAnn V ^b   Gass, Margery L S ^c   Dorin, Maxine H ^d   Ronkin, Sheila ^e   Pickar, James H ^e   Constantine, Ginger ^e  

^a NewYork Presbyterian Hospital   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^e PFIZER INC   (United States)

Author keywords

Bazedoxifene; breast pain; coagulation; conjugated estrogens; hot flushes; metabolism; vaginal atrophy

Indexed keywords

ANTITHROMBIN III; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; BAZEDOXIFENE; CONJUGATED ESTROGEN; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PROTEIN C; PROTEIN S; RALOXIFENE; TRIACYLGLYCEROL;

ABDOMINAL PAIN; ADULT; AGED; AMINO ACID METABOLISM; ARTHRALGIA; ARTICLE; BACKACHE; BLOOD CLOTTING; CARBOHYDRATE METABOLISM; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEEP VEIN THROMBOSIS; DIARRHEA; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HEART INFARCTION; HOT FLUSH; HUMAN; INFECTION; INFLUENZA; INSOMNIA; ISCHEMIC HEART DISEASE; LARYNX PAIN; LIMB PAIN; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MASTALGIA; MENOPAUSAL SYNDROME; MULTICENTER STUDY; MUSCLE SPASM; MYALGIA; NAUSEA; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PHLEBITIS; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA VEIN OCCLUSION; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; SORE THROAT; TRIACYLGLYCEROL BLOOD LEVEL; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VAGINA ATROPHY; VENOUS THROMBOEMBOLISM;

ADULT; AGED; ATROPHY; CARBOHYDRATE METABOLISM; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ESTROGENS; ESTROGENS, CONJUGATED (USP); FEMALE; HOMOCYSTEINE; HOT FLASHES; HUMANS; INDOLES; LIPID METABOLISM; MENOPAUSE; MIDDLE AGED; OUTPATIENTS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TREATMENT OUTCOME; VAGINA;

EID: 69049120132     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2009.03.113     Document Type: Article

References (24)

1. Population Division U.S. Census Bureau. Table 1: Annual estimates of the population by sex and five-year age groups for the United States: April 1, 2000 to July 1, 2007. NC-EST2007-01. May 2008.
2. Lobo R.A., Belisle S., Creasman W.T., Frankel N.R., Goodman N.E., Hall J.E., et al. Should symptomatic menopausal women be offered hormone therapy?. Med Gen Med 8 (2006) 1
3. National Osteoporosis Foundation. Fast Facts. Available at http://www.nof.org/osteoporosis/diseasefacts.htm. Accessed January 29, 2007.
4. Miller P.D., Chines A.A., Christiansen C., Hoeck H.C., Kendler D.L., Lewiecki E.M., et al. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res 23 (2008) 525-535
5. Silverman S.L., Christiansen C., Genant H.K., Vukicevic S., Zanchetta J.R., De Villiers T.J., et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo- and active-controlled clinical trial. J Bone Miner Res 23 (2008) 1923-1934
6. Gruber C., and Gruber D. Bazedoxifene (Wyeth). Curr Opin Investig Drugs 5 (2004) 1086-1093
7. Komm B.S., Kharode Y.P., Bodine P.V., Harris H.A., Miller C.P., and Lyttle C.R. Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology 146 (2005) 3999-4008
8. Ronkin S., Northington R., Baracat E., Nunes M.G., Archer D.F., Constantine G., et al. Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women. Obstet Gynecol 105 (2005) 1397-1404
9. Miller C.P., Harris H.A., and Komm B.S. Bazedoxifene acetate. Drugs Future 27 (2002) 117-121
10. Boudes P., Ronkin S., Korner P., Baracat E., and Constantine G. Effects of bazeoxifene (TSE-424), a novel tissue selective estrogen receptor modulator (SERM), on the incidence of breast pain. Osteoporos Int 14 (2003) S14
11. Van Duren D., Ronkin S., Pickar J., and Constantine G. Bazedoxifene combined with conjugated estrogens: a novel alternative to traditional home therapies. Fertil Steril 86 (2006) S88-S89
12. Pickar J.H., Yeh I.-T., Bachmann G., and Speroff L. Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy. Fertil Steril 92 (2009) 1018-1024
13. Lindsay R., Gallagher J.C., Kagan R., Pickar J.H., and Constantine G. Efficacy of tissue-selective estrogen complex (TSEC) of bazedoxifene/conjugated estrogens (BZA/CE) for osteoporosis prevention in at-risk postmenopausal women. Fertil Steril 92 (2009) 1045-1052
14. Archer D.F., Lewis V., Carr B.R., Olivier S., and Pickar J.H.. Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women. Fertil Steril 92 (2009) 1039-1044
15. Walton C., Godsland I.F., Proudler A.J., Wynn V., and Stevenson J.C. The effects of the menopause on insulin sensitivity, secretion and elimination in non-obese, healthy women. Eur J Clin Invest 23 (1993) 466-473
16. Spencer C.P., Godsland I.F., and Stevenson J.C. Is there a menopausal metabolic syndrome?. Gynecol Endocrinol 11 (1997) 341-355
17. Lobo R.A. Lipids, clotting factors, and diabetes: endogenous risk factors for cardiovascular disease. Am J Obstet Gynecol 158 (1988) 1584-1591
18. Mosca L., Grundy S.M., Judelson D., King K., Limacher M., Oparil S., et al. Guide to preventive cardiology for women. AHA/ACC Scientific Statement Consensus Panel statement. Circulation 99 (1999) 2480-2484
19. Manolio T.A., Pearson T.A., Wenger N.K., Barrett-Connor E., Payne G.H., and Harlan W.R. Cholesterol and heart disease in older persons and women. Review of an NHLBI workshop. Ann Epidemiol 2 (1992) 161-176
20. Bass K.M., Newschaffer C.J., Klag M.J., and Bush T.L. Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med 153 (1993) 2209-2216
21. Lobo R.A., Pickar J.H., Wild R.A., Walsh B., and Hirvonen E. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. The Menopause Study Group. Obstet Gynecol 84 (1994) 987-995
22. Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. J Am Med Assoc 273 (1995) 199-208
23. Lobo R.A., Bush T., Carr B.R., and Pickar J.H. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. Fertil Steril 76 (2001) 13-24
24. Shlipak M.G., Simon J.A., Vittinghoff E., Lin F., Barrett-Connor E., Knopp R.H., et al. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. J Am Med Assoc 283 (2000) 1845-1852